Danaher Corporation

Danaher earns two kinds of revenue, by its own account: recurring income from consumables, services and equipment leases tied to instruments already placed with customers, and nonrecurring income from selling new instruments and point-in-time software licenses. Across the annual periods CompanyGraph has recomputed from its financial statements, this mix has produced a profit every year.

CompanyGraph classifies Danaher alongside a very large number of companies that run the same kind of production-and-conversion system, so the basic shape of its business is common rather than rare. Within that group, its recomputed cash-flow figures sit toward the upper end of the range CompanyGraph benchmarks against industry peers: operating cash flow captures an unusually large share of revenue, and free cash flow keeps an unusually large share of that operating cash flow, meaning capital spending claims comparatively little of what the business generates. CompanyGraph reads this as consistent with a system that scales less by adding manufacturing capacity in step with revenue and more by growing the recurring consumables, services and software attached to instruments already placed with customers; that reading is an interpretation, not something stated directly in the underlying figures.

By its own account, some of Danaher's businesses depend on sole or limited-source suppliers for certain components, chosen for reasons such as quality assurance, regulatory requirements, cost or availability, while its broader raw-material purchasing draws on a large number of suppliers worldwide. It also depends on business partners for some development, supply and marketing arrangements, on key distributors and channel partners for a meaningful part of its sales, on outside technology and IT providers, and on regulatory approval of its own manufacturing facilities before certain products can be produced.

By its own account, the buyers of what Danaher sells are businesses and institutions: pharmaceutical and biotechnology companies, contract manufacturers, academic and commercial researchers, universities and medical schools, industrial manufacturers, hospitals, physicians' offices, reference laboratories and blood banks. It names no consumer segment, and its filings do not disclose how concentrated its revenue is among these buyers.

The basic production shape Danaher runs is shared by a very large number of other companies CompanyGraph classifies the same way, so operating this kind of business is not on its own a source of distinction. By its own account, Danaher says it holds a leadership position in many of the markets it serves, but it also says it cannot state its aggregate or segment competitive position accurately because no single competitor sells the same combination of product lines into the same markets, and it discloses no market-share figure to support the leadership claim.

By its own account, a meaningful share of Danaher's future revenue is already committed under contracts whose original terms run longer than a year, and a large part of that committed revenue is not expected to convert into recognized revenue for some time yet. Its revenue model itself relies on recurring income from consumables, services and equipment leases tied to instruments already placed with customers, rather than on one-time equipment sales alone, so part of its revenue depends on customers continuing to use what they have already installed rather than on new purchase decisions.

Danaher's own filings do not name one specific limit on how large the company can grow. They say manufacturing capacity has at times run ahead of what production needed and at other times fallen behind it, and that interruptions in its supply chain can delay production and extend how long orders take to fill.

By its own account, Danaher's specific exposures include dependence on sole or limited-source suppliers for some components, dependence on regulatory approval before some of its own manufacturing facilities can produce certain products, and earning more revenue than it spends in some non-U.S. currencies, so movement in those currencies against the dollar affects what it reports. The risks it lists first in its own disclosures are broad economic and financial-market conditions, competition that can reduce demand, market share or prices, and whether new products it develops are successfully commercialized and accepted.

By its own account, the risks Danaher lists first are broad economic and financial-market conditions, competition that can reduce demand, market share or prices, and whether the new and enhanced products it develops are successfully commercialized and accepted by customers. It also names currency movement as a pressure, since it earns more revenue than it spends in some non-U.S. currencies, and it names dependence on regulatory approval of its own manufacturing facilities and on political, legal and trade conditions outside the United States.